Literature DB >> 30476008

Novel roles of mechanistic target of rapamycin signaling in regulating fetal growth†.

Madhulika B Gupta1,2,3, Thomas Jansson4.   

Abstract

Mechanistic target of rapamycin (mTOR) signaling functions as a central regulator of cellular metabolism, growth, and survival in response to hormones, growth factors, nutrients, energy, and stress signals. Mechanistic TOR is therefore critical for the growth of most fetal organs, and global mTOR deletion is embryonic lethal. This review discusses emerging evidence suggesting that mTOR signaling also has a role as a critical hub in the overall homeostatic control of fetal growth, adjusting the fetal growth trajectory according to the ability of the maternal supply line to support fetal growth. In the fetus, liver mTOR governs the secretion and phosphorylation of insulin-like growth factor binding protein 1 (IGFBP-1) thereby controlling the bioavailability of insulin-like growth factors (IGF-I and IGF-II), which function as important growth hormones during fetal life. In the placenta, mTOR responds to a large number of growth-related signals, including amino acids, glucose, oxygen, folate, and growth factors, to regulate trophoblast mitochondrial respiration, nutrient transport, and protein synthesis, thereby influencing fetal growth. In the maternal compartment, mTOR is an integral part of a decidual nutrient sensor which links oxygen and nutrient availability to the phosphorylation of IGFBP-1 with preferential effects on the bioavailability of IGF-I in the maternal-fetal interface and in the maternal circulation. These new roles of mTOR signaling in the regulation fetal growth will help us better understand the molecular underpinnings of abnormal fetal growth, such as intrauterine growth restriction and fetal overgrowth, and may represent novel avenues for diagnostics and intervention in important pregnancy complications.
© The Author(s) 2018. Published by Oxford University Press on behalf of Society for the Study of Reproduction.

Entities:  

Keywords:  decidua; developmental origins of health and disease; fetal development; insulin-like growth factor; intrauterine growth restriction; kinases; metabolism; nutrition; placenta; placental transport; pregnancy; syncytiotrophoblast

Mesh:

Substances:

Year:  2019        PMID: 30476008      PMCID: PMC6698747          DOI: 10.1093/biolre/ioy249

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  182 in total

1.  Maternal insulin-like growth factors-I and -II act via different pathways to promote fetal growth.

Authors:  Amanda N Sferruzzi-Perri; Julie A Owens; Kirsty G Pringle; Jeffrey S Robinson; Claire T Roberts
Journal:  Endocrinology       Date:  2006-03-23       Impact factor: 4.736

2.  Regulation of fetal liver growth in a model of diet restriction in the pregnant rat.

Authors:  Joan M Boylan; Jennifer A Sanders; Philip A Gruppuso
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-06-29       Impact factor: 3.619

3.  IUGR Is Associated With Marked Hyperphosphorylation of Decidual and Maternal Plasma IGFBP-1.

Authors:  Madhulika B Gupta; Majida Abu Shehab; Karen Nygard; Kyle Biggar; Sahil S Singal; Nanette Santoro; Theresa L Powell; Thomas Jansson
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

Review 4.  Casein Kinase II: an attractive target for anti-cancer drug design.

Authors:  Ismail Muhamad Hanif; Ibrahim Muhammad Hanif; Muhammad Ali Shazib; Kashif Adil Ahmad; Shazib Pervaiz
Journal:  Int J Biochem Cell Biol       Date:  2010-06-15       Impact factor: 5.085

5.  Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction.

Authors:  Majida Abu Shehab; Ian Damerill; Tong Shen; Fredrick J Rosario; Mark Nijland; Peter W Nathanielsz; Amrita Kamat; Thomas Jansson; Madhulika B Gupta
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

6.  Activation of placental insulin and mTOR signaling in a mouse model of maternal obesity associated with fetal overgrowth.

Authors:  Fredrick J Rosario; Theresa L Powell; Thomas Jansson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

7.  L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway.

Authors:  Latif Rachdi; Virginie Aïello; Bertrand Duvillié; Raphaël Scharfmann
Journal:  Diabetes       Date:  2011-12-30       Impact factor: 9.461

8.  Maternal folate deficiency causes inhibition of mTOR signaling, down-regulation of placental amino acid transporters and fetal growth restriction in mice.

Authors:  Fredrick J Rosario; Peter W Nathanielsz; Theresa L Powell; Thomas Jansson
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

9.  Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.

Authors:  Angli Xue; Yang Wu; Zhihong Zhu; Futao Zhang; Kathryn E Kemper; Zhili Zheng; Loic Yengo; Luke R Lloyd-Jones; Julia Sidorenko; Yeda Wu; Allan F McRae; Peter M Visscher; Jian Zeng; Jian Yang
Journal:  Nat Commun       Date:  2018-07-27       Impact factor: 14.919

10.  Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth.

Authors:  Yi Zhu; Karla M P Pires; Kevin J Whitehead; Curtis D Olsen; Benjamin Wayment; Yi Cheng Zhang; Heiko Bugger; Olesya Ilkun; Sheldon E Litwin; George Thomas; Sara C Kozma; E Dale Abel
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more
  14 in total

1.  Hyperphosphorylation of fetal liver IGFBP-1 precedes slowing of fetal growth in nutrient-restricted baboons and may be a mechanism underlying IUGR.

Authors:  Jenica H Kakadia; Bhawani B Jain; Kyle Biggar; Austen Sutherland; Karen Nygard; Cun Li; Peter W Nathanielsz; Thomas Jansson; Madhulika B Gupta
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-08-03       Impact factor: 4.310

2.  Infant Mesenchymal Stem Cell Insulin Action Is Associated With Maternal Plasma Free Fatty Acids, Independent of Obesity Status: The Healthy Start Study.

Authors:  Alec B Chaves; Donghai Zheng; Jonathan A Johnson; Bryan C Bergman; Zachary W Patinkin; Vincent Zaegel; Ericka M Biagioni; Polina Krassovskaia; Nicholas T Broskey; Linda E May; Dana Dabelea; Joseph A Houmard; Kristen E Boyle
Journal:  Diabetes       Date:  2022-08-01       Impact factor: 9.337

3.  Mechanistic Target of Rapamycin Complex 1: From a Nutrient Sensor to a Key Regulator of Metabolism and Health.

Authors:  Guoyan Wang; Lei Chen; Senlin Qin; Tingting Zhang; Junhu Yao; Yanglei Yi; Lu Deng
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

4.  Uteroplacental nutrient flux and evidence for metabolic reprogramming during sustained hypoxemia.

Authors:  Amanda K Jones; Paul J Rozance; Laura D Brown; Ramón A Lorca; Colleen G Julian; Lorna G Moore; Sean W Limesand; Stephanie R Wesolowski
Journal:  Physiol Rep       Date:  2021-09

5.  Increased uterine artery blood flow in hypoxic murine pregnancy is not sufficient to prevent fetal growth restriction†.

Authors:  Sydney L Lane; Alexandrea S Doyle; Elise S Bales; Ramón A Lorca; Colleen G Julian; Lorna G Moore
Journal:  Biol Reprod       Date:  2020-03-13       Impact factor: 4.285

Review 6.  Placental function in maternal obesity.

Authors:  Amy C Kelly; Theresa L Powell; Thomas Jansson
Journal:  Clin Sci (Lond)       Date:  2020-04-30       Impact factor: 6.124

Review 7.  Placental Function and the Development of Fetal Overgrowth and Fetal Growth Restriction.

Authors:  Jerad H Dumolt; Theresa L Powell; Thomas Jansson
Journal:  Obstet Gynecol Clin North Am       Date:  2021-06       Impact factor: 2.838

8.  Effect of type 2 diabetes mellitus on placental expression and activity of nutrient transporters and their association with birth weight and neonatal adiposity.

Authors:  Marisol Castillo-Castrejon; Kyohei Yamaguchi; Rachel L Rodel; Kathryn Erickson; Anita Kramer; Nicole M Hirsch; Kristy Rolloff; Thomas Jansson; Linda A Barbour; Theresa L Powell
Journal:  Mol Cell Endocrinol       Date:  2021-05-12       Impact factor: 4.369

Review 9.  Developmental origins of metabolic diseases.

Authors:  Daniel J Hoffman; Theresa L Powell; Emily S Barrett; Daniel B Hardy
Journal:  Physiol Rev       Date:  2020-12-03       Impact factor: 46.500

10.  Inhibition of 2-Oxoglutarate Dehydrogenase as a Chemical Model of Acute Hypobaric Hypoxia.

Authors:  Anastasia Graf; Alexander Ksenofontov; Victoria Bunik
Journal:  Front Med (Lausanne)       Date:  2021-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.